Related by context. All words. (Click for frequent words.) 78 randomized trials 76 randomized controlled trials 76 randomized clinical trials 76 meta analysis 75 observational studies 74 RCTs 71 randomized controlled trials RCTs 70 randomized controlled clinical trials 68 placebo controlled trials 67 placebo controlled studies 67 epidemiological studies 66 Meta analyzes 65 subgroup analyzes 65 epidemiologic studies 64 multicenter trials 64 metaanalysis 63 trials RCTs 63 placebo controlled clinical trials 63 prospective observational studies 62 nonrandomized 62 methodological limitations 62 nonrandomized studies 61 NEJM 61 Systematic reviews 61 ALLHAT 61 selenium supplementation 61 VADT 60 methodologic 60 Cochrane reviewers 60 correlational 60 randomized controlled trial 60 RE LY 60 longitudinal studies 60 Observational studies 60 ConclusionThis 59 INTERHEART study 59 postmarketing surveillance 59 BARI 2D 59 generalisability 58 confounding variables 58 IMPROVE HF 58 Cochrane Database 58 Cochrane Systematic Review 58 KRAS variant 58 antihypertensive medications 58 Subgroup analyzes 58 meta analytic 58 Intervention Effectiveness CATIE 58 psychotherapies 58 PROactive study 58 HCV SPRINT 58 generalizability 58 regression analyzes 58 postmenopausal hormone therapy 58 ACCORD Lipid 58 antihypertensive therapy 58 randomized clinical 58 IQWiG 58 candesartan 58 glitazones 58 SGAs 57 reboxetine 57 statins 57 RE LY ® 57 antioxidant supplements 57 GnRH agonists 57 angiotensin receptor blockers 57 multivariate analyzes 57 rosiglitazone 57 UKPDS 57 retrospective cohort 57 antihypertensive drugs 57 prospective randomized controlled 57 meta analysis pooling 57 pharmacological interventions 57 SCD HeFT 57 periprocedural MI 57 neuroimaging studies 57 Clinical Antipsychotic Trials 57 genomewide association studies 56 meta regression 56 nonpharmacologic 56 prospective longitudinal 56 aldosterone antagonist 56 calcium supplementation 56 subanalysis 56 Systematic Reviews 56 nesiritide 56 methodological flaws 56 Prostate Cancer Prevention 56 observational study 56 vitro studies 56 coxibs 56 Intervention Trial GAIT 56 antiplatelet agents 56 prognostic factors 56 convergent validity 56 Randomized trials 56 Stenting Trial CREST 56 statin medications 56 vitamin D supplementation 56 neuropsychiatric symptoms 56 newer atypical antipsychotics 56 HORIZONS AMI trial 56 placebo controlled clinical 56 thiazolidinediones 56 randomized controlled 56 β blockers 56 Nissen meta analysis 56 adalimumab 56 ExTRACT TIMI 56 testosterone supplementation 56 intravenous bisphosphonates 56 nomograms 55 studies 55 phase IIIb 55 logistic regression models 55 lipid lowering therapy 55 methodologically sound 55 RTOG 55 ONTARGET 55 lipid abnormalities 55 BoNTA 55 multicentre 55 psychodynamic therapy 55 pharmacologic treatments 55 tibolone 55 topical NSAIDs 55 antiplatelet drugs 55 ENDEAVOR clinical 55 antiepileptics 55 randomized controlled clinical 55 conditional logistic regression 55 antidepressant efficacy 55 APPROVe 55 chlorthalidone 55 DAPT 55 HYVET 55 newer antipsychotics 55 strontium ranelate 55 rosiglitazone Avandia 55 TRITON TIMI 55 ECASS 55 routine episiotomy 55 Lipid Lowering Treatment 55 active comparator 55 atypicals 55 multicenter 55 commonly prescribed antidepressants 55 antiepileptic drugs 54 homocysteine lowering 54 lipid lowering drugs 54 pharmacogenetic testing 54 CALGB 54 statin 54 methodologically rigorous 54 susceptibility loci 54 rEEG 54 multicenter placebo controlled 54 paricalcitol 54 #F FDG PET 54 cilostazol 54 aripiprazole Abilify 54 prospective randomized placebo 54 SpHb monitoring 54 NSAIDs 54 lipid lowering agents 54 pharmacological approaches 54 fluvastatin 54 unmeasured confounders 54 Reynolds Risk Score 54 sertraline 54 Randomized controlled 54 androgen suppression 54 teriparatide 54 ACC AHA 54 post hoc 54 thiazide diuretics 54 Multiple logistic regression 54 Digital Mammographic Imaging 54 HMG CoA reductase inhibitors 54 pioglitazone Actos 54 peer reviewed 54 mycophenolate mofetil 54 dyslipidaemia 54 prospective randomized 54 prospective observational cohort 54 NICE SUGAR 54 metabolic parameters 54 aldosterone antagonists 54 EURIDIS 54 pioglitazone 54 dosage regimens 54 univariate 54 prospectively defined 54 HOPE TOO 54 Protelos 54 BOLDER II 54 cardiovascular morbidity 54 coinvestigators 54 CYPHER Stent 54 oncologic outcomes 54 statin therapy 54 infantile colic 54 Lancet Neurology 54 Bonferroni correction 54 genotypic 54 prucalopride 54 Carotid Revascularization Endarterectomy vs. 54 secretin 54 psychodynamic psychotherapy 54 HIVNET 54 RE LY trial 54 Prostate Lung Colorectal 54 Cholesterol Levels SPARCL 54 dabigatran 54 Dr. Roehrborn 54 chemoprevention trials 54 Intervention Effectiveness 54 dietary modification 54 tricyclic antidepressants 53 logistic regression analyzes 53 serotonin reuptake inhibitors 53 liver biopsies 53 fibrate 53 methodological weaknesses 53 SPARCL 53 immunohistochemical 53 MADIT CRT trial 53 residual confounding 53 paclitaxel eluting stents 53 Bresalier 53 adjuvant therapies 53 Subgroup analysis 53 liver transplant recipients 53 blinded randomized controlled 53 EEG abnormalities 53 ticagrelor 53 riociguat 53 BJU International 53 Edge STudy 53 risperidone Risperdal 53 CARE HF 53 SABCS 53 exploratory endpoints 53 Glucosamine chondroitin Arthritis 53 APPRAISE 53 CYPHER R Sirolimus eluting 53 spinal manipulation 53 journal Ophthalmology 53 cardioprotective effects 53 STEP BD 53 oral diclofenac 53 idraparinux 53 beta blocker therapy 53 Diabetologia 53 darunavir ritonavir 53 CTEPH 53 Clinical Psychiatry 53 eprotirome 53 AVERROES 53 Health Initiative WHI 53 tocilizumab 53 atypical antipsychotics 53 substudy 53 antioxidant supplementation 53 macrovascular disease 53 elevated CRP 53 morphometric vertebral fractures 53 WHEL 53 pairwise comparisons 53 biologic plausibility 53 antiplatelet therapies 53 coinfected patients 53 CAM modalities 53 efficacy endpoints 53 cerebral microbleeds 53 bivariate analyzes 53 clinically meaningful differences 53 neuroleptics 53 MDRD equation 53 randomized multicenter 53 Serebruany 53 generalisable 53 EUS FNA 53 glucose lowering 53 multicenter study 53 heartwire 53 Sackner Bernstein 53 colorectal neoplasia 53 ARCOXIA 53 pharmacoeconomic analysis 53 MERLIN TIMI 53 NCCAM 53 noninferiority 53 interpersonal psychotherapy 53 placebo controlled 53 NATRECOR ® 53 genetic polymorphisms 53 genotypic resistance 53 prognostic variables 53 left ventricular dysfunction 53 atorvastatin Lipitor 53 ISAR REACT 53 NSABP B 53 biological plausibility 53 F FDG PET 53 factorial design 53 microarray experiments 53 non selective NSAIDs 53 prospective observational 52 SSRIs 52 vertebroplasty 52 nonvertebral fractures 52 Celecoxib APC trial 52 nonfatal MI 52 beta carotene supplementation 52 Arch Surg 52 hypertensive patients 52 peer reviewed publications 52 NCCTG N# 52 fluoxetine Prozac 52 postoperative mortality 52 CLBP 52 radiographic outcomes 52 dose statin therapy 52 Vauthey 52 peer reviewed journals 52 coxib 52 PRECiSE 52 Diabetic Medicine 52 generation antipsychotics 52 causal inference 52 nephron sparing surgery 52 Aggressive Reduction 52 double blinded randomized 52 secondary efficacy endpoints 52 PLCO 52 tiotropium 52 randomized placebo controlled 52 rofecoxib 52 colorectal adenoma 52 insulin glargine 52 J Clin Oncol 52 multicenter randomized 52 Evaluation WISE 52 MADIT II 52 teriflunomide 52 Baseline characteristics 52 ATACAND 52 glatiramer acetate 52 Winkelmayer 52 prospective nonrandomized 52 empiric 52 cardiac toxicity 52 fluoxetine paroxetine 52 revascularization procedures 52 Cochrane Library 52 ERSPC 52 comorbidities 52 fibrates 52 MMSE scores 52 angiotensin II receptor blockers 52 KRAS status 52 observational cohort 52 TAXUS IV 52 deferiprone 52 covariate 52 antitumor effect 52 renoprotective 52 direct thrombin inhibitors 52 immunosuppressive agents 52 HAART regimens 52 TZDs 52 Randomized Controlled Trials 52 Logistic regression 52 lipid parameters 52 hydroxyvitamin D levels 52 preclinical efficacy 52 multivariate regression analysis 52 univariate analyzes 52 estrogen progestin therapy 52 Women Ischemia Syndrome 52 antihypertensive agents 52 postmenopausal hormones 52 Intervention Trial 52 Non inferiority 52 clinically meaningful 52 sotalol 52 MGUS 52 Doxil ® 52 retrospective cohort study 52 follicular adenoma 52 mammographic density 52 canakinumab 52 AIM HIGH 52 cediranib 52 inhaled anticholinergics 52 NNT = 52 dietary interventions 52 stone formers 52 PROSTVAC TM 52 phosphate binders 52 vitro experiments 52 adenotonsillectomy 52 postmarketing 52 chromium picolinate supplementation 52 retrospective observational 52 number NCT# ClinicalTrials.gov 52 AIR2 Trial 52 Vertos II 52 ginkgo extract 52 QT prolongation 52 prospective multicentre 52 anticholinergic drugs 52 methodological shortcomings 52 statin drugs 52 carotid stents 52 confirmatory clinical 52 celecoxib 52 HyQ 52 ClinicalTrials.gov 52 BCIRG 52 postoperative chemotherapy 52 atherothrombotic disease 52 Gøtzsche 52 hemoglobin A1c levels 52 intensive statin therapy 52 anastrozole 52 SYNTAX 52 LDL lowering 52 tolvaptan 52 peer reviewed literature 52 Poisson regression 52 USPSTF 52 NSAID 52 WHI 52 pathogenetic mechanisms 52 intact parathyroid hormone 51 rosuvastatin 51 NATRECOR R 51 pharmacotherapies 51 ACCORD ADVANCE 51 paroxetine Paxil 51 Epidemiologic studies 51 GFT# 51 NHANES III 51 alexithymia 51 comorbidity 51 clinical trials 51 placebo controlled randomized 51 oral bisphosphonates 51 statistical significance 51 efficacy 51 radical nephrectomy 51 Celebrex celecoxib 51 journal Urology 51 thimerosal exposure 51 perfusion CT 51 composite endpoint 51 rosuvastatin Crestor 51 cystatin C 51 renal tumors 51 telcagepant 51 amisulpride 51 ROCKET AF 51 loop diuretics 51 Ann Oncol 51 nondiabetic patients 51 STRIDE PD 51 gadobutrol 51 oral bisphosphonate 51 Celecoxib 51 conventional angiography 51 predictive validity 51 macrovascular 51 confounders 51 multiple logistic regression 51 diuretic chlorthalidone 51 Crestor rosuvastatin 51 myocardial infarctions MIs 51 COX inhibitors 51 breast cancer recurrences 51 PREVENT IV 51 lipid lowering therapies 51 ASCEND HF 51 Ovarian PLCO Cancer 51 clinical pharmacology studies 51 sentinel node biopsy 51 hormone therapy estrogen 51 DSMB 51 comorbid conditions 51 ischemic cardiovascular 51 neoadjuvant 51 analgesic efficacy 51 nonoperative 51 Edward Giovannucci 51 NNRTI resistance 51 fibrate drugs 51 cholinesterase inhibitors 51 Multivariate logistic regression 51 multicentre randomized 51 MDRD 51 venlafaxine Effexor 51 vitamin D inadequacy 51 multivariable analysis 51 corticosteroid injections 51 Medicine NEJM 51 ACUITY trial 51 abatacept 51 valsartan 51 myocardial infarctions 51 KIF6 carriers 51 probiotic supplementation 51 nomogram 51 polyarticular 51 leukotriene receptor antagonists 51 psychopharmacological 51 HIV HCV coinfected 51 newer antipsychotic medications 51 Psychosomatic Research 51 SORT OUT III 51 antidiabetic drugs 51 TAXUS VI 51 PRIMO CABG2 51 Mechanistic studies 51 anticonvulsants 51 GOUT 51 Kruskal Wallis test 51 colorectal liver metastases 51 nonadherence 51 tipranavir 51 nonparametric 51 Avandia rosiglitazone 51 CAMMS# 51 homocysteine concentrations 51 myopathy rhabdomyolysis 51 NHANES 51 anticonvulsant drugs 51 donepezil 51 beta carotene supplements 51 SPIRIT IV 51 prospective cohort 51 lymphadenectomy 51 SYNTAX trial 51 Randomized clinical trials 51 PLCO trial 51 unmeasured factors 51 chest radiographs 51 prespecified 51 journal Lancet Neurology 51 JAMA 51 PREZISTA r 51 Framingham Offspring Study 51 rFVIIa 51 drug eluting stents 51 PERSEUS 51 viral kinetic 51 fondaparinux 51 warfarin therapy 51 confounder 51 poor metabolizers 51 Multiple linear regression 51 hydroxychloroquine 51 Screening Trial DMIST 51 plasma pharmacokinetics 51 APTIVUS r 51 diagnosing ADHD 51 toxicological studies 51 preoperative MRI 51 biopsychosocial 51 immunohistochemical staining 51 bivariate 51 RECORD1 51 risedronate 51 pharmacological therapies 51 Roxana Mehran MD 51 TNF inhibitors 51 aspirin clopidogrel 51 intracranial stenosis 51 microvascular complications 51 multivariate Cox 51 clinicopathological 51 Prostate AdenoCarcinoma Treatment 51 Nesiritide 51 antithrombotic therapy 51 pyridostigmine 51 ASTEROID 51 preoperative chemotherapy 51 prasugrel Effient 51 pegylated liposomal doxorubicin 51 titrated glipizide 51 efficacy endpoint 51 inhaled steroids 51 dose regimens 51 COX 2s 51 angiotensin converting enzyme inhibitors 51 Resolute DES 51 viral kinetics 51 Study AREDS 51 randomized multicenter trial 51 non aspirin NSAIDs 51 nonselective NSAIDs 51 HeFT 51 inhaled corticosteroids 51 Longitudinal studies 51 QRISK 51 folate intake 51 epidemiologic 51 Interphone study 51 trastuzumab Herceptin ® 51 ß blockers 51 AJCN 51 acamprosate 51 journal Psychotherapy 51 endarterectomy 51 typical antipsychotics 50 AVOREN 50 MADIT CRT 50 SSRI antidepressants 50 menopausal hormone therapy 50 prospectively randomized 50 CHARISMA trial 50 Kaplan Meier curve 50 clinicopathologic 50 pharmacological treatments 50 Clinical Psychopharmacology 50 genomewide 50 CANCIDAS 50 chromium supplementation 50 DCCT 50 angiographic outcomes 50 CYPHER ® Stent 50 Heritability 50 Multivariate analysis 50 basal bolus regimen 50 perphenazine 50 colorectal neoplasms 50 statin simvastatin 50 perinatal outcomes 50 ARB telmisartan 50 chemoradiotherapy 50 intravesical therapy 50 lipid lowering medication 50 postmenopausal osteoporotic women 50 Avandia Actos 50 glargine 50 CHD mortality 50 antiplatelet therapy 50 journal Resuscitation 50 carotid stenting 50 Antihypertensive 50 borderline statistical significance 50 Lp PLA2 50 postoperative complications 50 Arch Intern Med 50 bezafibrate 50 infliximab Remicade 50 ginkgo biloba extract 50 LUX Lung 50 cranial irradiation 50 Meta Analysis 50 dietary intakes 50 histologic subtypes 50 hemostatic efficacy 50 contralateral breast cancer 50 solifenacin 50 ANOVA 50 multivariate logistic regression 50 Natural S equol 50 sulfasalazine 50 randomized 50 Lp PLA 2 50 carotid artery stenting 50 abstracts summarizing 50 confounding factors 50 CVD mortality 50 ACCOMPLISH 50 familial aggregation 50 Observational Study 50 thromboprophylaxis 50 glycoprotein IIb IIIa inhibitors 50 venous thromboembolisms 50 bosentan 50 asymptomatic carotid stenosis 50 syndromal 50 Candesartan 50 paroxysmal AF 50 FOLPI 50 BRCA testing 50 prostate carcinogenesis 50 HbA 1c 50 immunosuppressive therapies 50 NCT# ClinicalTrials.gov 50 antiandrogens 50 nonclinical studies 50 sildenafil Viagra 50 prognostic markers 50 oncological outcomes 50 warfarin 50 safinamide 50 Taxus Stent 50 HbA1c levels 50 pre menopausal 50 Truvada tablets 50 antithrombotic agents 50 isoflavone supplement 50 pharmacokinetic PK 50 biostatistical 50 carotid stenosis 50 LDL particle 50 macrovascular events 50 sirolimus stent 50 Aprotinin 50 Histopathological 50 BMC Musculoskeletal Disorders 50 CALGB # [002] 50 Laryngoscope 50 Neuropsychologia 50 ziprasidone Geodon 50 fructose intake 50 incomplete revascularization 50 genetic variants associated 50 clomipramine 50 glycemia 50 valsartan Diovan 50 EVEREST II 50 tipranavir ritonavir 50 Cleft Palate Craniofacial 50 adjuvant therapy 50 HRQL 50 genetic loci 50 variance ANOVA 50 tamoxifen raloxifene 50 BOLDER 50 Wisconsin Sleep Cohort 50 Chicago Multidisciplinary Symposium 50 thrombotic events 50 PSA screening 50 sulphonylureas 50 eplerenone 50 folate supplementation 50 TZD 50 telomere lengths 50 atypical antipsychotic medications 50 methodological differences 50 metastatic RCC 50 CLA supplementation 50 Cochrane Collaboration 50 placebo controlled multicenter 50 IMPROVE IT 50 oral antidiabetic 50 journal Pharmacoepidemiology 50 magnesium supplementation 50 landmark ATHENA study 50 adjuvant chemotherapy 50 Schizophrenia Bulletin 50 inhaled corticosteroid therapy 50 CombAT 50 NSABP 50 tumor histology 50 TAXUS Liberte Stent 50 telmisartan 50 Trandolapril 50 methodologically flawed 50 lipid lowering 50 mg doses 50 NO# [002] 50 Xelox 50 clinically relevant 50 MMP inhibitors 50 Prozac fluoxetine 50 surrogate markers 50 FDG PET scans 50 bile acid metabolism 50 journal BJU International 50 chemopreventive agents 50 Outpatient Setting 50 ziprasidone 50 venous thromboembolism prophylaxis 50 nulliparous women 50 REACH Registry 50 DHEA supplementation 50 tamoxifen therapy 50 Bonferroni 50 antiarrhythmic drug 50 gabapentin Neurontin 50 pazopanib 50 pharmacokinetic characteristics 50 TOHP 50 Relieve Depression 50 ancrod 50 cardiovascular mortality 50 FDG PET 50 pure fructose 50 antidepressant medications 50 causal inferences 50 chronic LBP 50 NMDA receptor antagonists 50 Afatinib 50 ACRIN 50 Shelley Salpeter 50 psychiatric diagnoses 50 carotid IMT 50 Francesca Bravi 50 selective serotonin reuptake inhibitor 50 anti arrhythmic drug 50 Val HeFT 50 Vectibix monotherapy 50 double blinded placebo 50 pharmacodynamic parameters 50 stepwise logistic regression 50 BR.# study 50 thyrotropin levels 50 antibiotic regimens 50 SEISMIC Trial 50 DASH diet 50 clopidogrel pretreatment 50 multicenter clinical trials 50 neurodevelopmental outcome 50 subtrochanteric 50 HF ACTION 50 Am J Cardiol 50 peer reviewed scientific 50 Univariate 50 actigraphy 50 comorbid psychiatric disorders 50 CAM therapies 50 oophorectomy 50 antithrombotic therapies 50 Randomized 50 subclinical hypothyroidism 50 salmeterol 50 zoledronate 50 methotrexate therapy 50 non pharmacological interventions 50 pathophysiological mechanisms 50 TEAEs 50 Oreopoulos 50 antithrombotics 50 vildagliptin 50 antiangiogenic agents 50 Screening Trial 50 NeuroImage 50 longitudinal cohort 50 Complications Trial 50 cognitive behavioral therapies 50 HCV RESPOND 2 50 MMSE score 50 chemotherapy gemcitabine 50 lamotrigine 50 clinical endpoints 50 oral antidiabetic medication 50 molecular subtypes 50 dose proportionality 50 Arch Neurol 50 Lancet Neurology journal 50 concomitant medications 50 spironolactone 50 candesartan cilexetil 50 postprandial glycemia 50 thoracoscopic lobectomy 50 PRE SURGE 50 valvulopathy 50 antiepileptic drugs AEDs 49 enzastaurin 49 dietary folate intake 49 montelukast 49 DMIST 49 serum lipid levels 49 APTIVUS 49 MEDLINE 49 levosimendan 49 mechanistic studies 49 Aggressive Drug Evaluation 49 Pharmacotherapy 49 neuroleptic 49 atherosclerotic renal artery stenosis 49 logistic regression analysis 49 BRIM3 49 CAPRIE 49 prospective multicenter 49 virologic responses 49 agomelatine 49 surrogate endpoint 49 torcetrapib atorvastatin 49 urodynamic 49 sirolimus eluting stents 49 etiological 49 pregabalin 49 oral antidiabetes drugs 49 guggul 49 postmenopausal women 49 somatoform disorders 49 PIX# [002] 49 magnesium intake 49 COPD exacerbations 49 NSQIP 49 Teriflunomide 49 subclinical atherosclerosis 49 ivabradine 49 AREDS 49 aetiology 49 PLOS 49 aprotinin 49 folic acid supplementation 49 serum cholesterol 49 Primary endpoints 49 selective NSAIDs 49 multivariate analysis 49 immunological responses 49 revascularizations 49 Tumor Response 49 CATIE 49 Lancet 49 locoregional recurrence 49 logistic regressions 49 sipuleucel T 49 everolimus eluting stents 49 symptomatic VTE 49 Serious Adverse Events 49 superficial bladder cancer 49 beta agonists 49 valproate 49 micafungin 49 CROI 49 hamartomas 49 virological response 49 nonmelanoma skin cancers 49 afatinib 49 Kantarjian 49 Rheumatologists 49 oral antidiabetic agents 49 affective disorders 49 Randomised Study 49 sorafenib Nexavar 49 clopidogrel 49 PROactive Study 49 SNP rs# [002] 49 Randomized Clinical Trial 49 Michael F. Leitzmann 49 RoACTEMRA 49 bmj.com today 49 Neurochemistry 49 muraglitazar 49 randomizing patients 49 journal Hepatology 49 Trial PCPT 49 BEIR 49 Braunwald 49 ritonavir boosted 49 nondiabetics 49 physiologic mechanisms 49 methotrexate monotherapy 49 TMC# C# 49 etiologic 49 breast cancer subtypes 49 lacosamide 49 genomewide association study 49 chemoradiation 49 hepatotoxicity 49 bisphosphonate drugs 49 null hypothesis 49 cox 2s 49 dietary antioxidants 49 ICD implantations 49 urothelial cancer 49 journal Diabetologia 49 clevidipine 49 journal Anesthesiology 49 Ascherio 49 Pharmacologic 49 thrombophilia 49 methodological 49 oral rivaroxaban 49 subscale scores 49 lipid lowering medications 49 Dtsch Arztebl Int 49 randomized Phase III 49 Antioxidant supplements 49 Dickersin 49 DMARD 49 SSRI 49 EMBO Molecular Medicine 49 Myerburg 49 serum creatinine levels 49 cerebrovascular events 49 reinfarction 49 coronary calcification 49 vismodegib 49 Clinical Outcomes Utilizing Revascularization 49 azacitidine 49 ACEIs 49 irbesartan 49 creatine supplementation 49 EuroIntervention 49 antithrombotic 49 ACTIVE W 49 Proellex TM